NanoPro Rx™ is a lipid-albumin stabilized solid nanoparticle. The technology enables the production of solid nanoparticles containing the water-insoluble drug, e.g., docetaxel, along with lipids and human albumin lyophilized into a powdered form. The powdered formulation is reconstituted to form a stable aqueous nanoparticle suspension with an average size of fewer than 100 nanometers (nm) before administration. The reconstituted suspension is free from the Ostwald Ripening effect and can maintain constant particle size for up to 5 days at 25°C. The Oswald Ripening effect refers to the growth of particles in a medium such as water due to the coexistence of particles with a broad size range.

NanoPro Rx™ allows us to create products for diseases or disorders in which no drug is available; or to create faster less invasive ways of conducting current medical diagnostics.

Avagen’s innovative and patented nano-technology drug delivery platform increases safety by removing toxic solubilizers associated with most chemotherapy formulations of poorly water-soluble molecules. By doing this, Avagen is also able to improve efficacy by increasing the dose and/or reducing drug resistance by incorporating additional sensitizer molecules into its multidrug capable solid nanoparticles.